| アブストラクト | OBJECTIVE: Venlafaxine, a serotonin-norepinephrine reuptake inhibitor widely prescribed for major depressive disorder and related conditions, remains insufficiently characterized regarding its adverse event profile. This study aimed to comprehensively evaluate the post-marketing safety of venlafaxine using data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). METHODS: The data were extracted from the FAERS database from the first quarter (Q1) 2004 to Q2 2025. Adverse drug events were analyzed using the Reporting Odds Ratio (ROR), Bayesian Confidence Propagation Neural Network (BCPNN), Proportional Reporting Ratio (PRR), and Multi-Item Gamma Poisson Shrinker (MGPS) methods. RESULTS: A total of 47,325 venlafaxine-related adverse event reports were analyzed. Disproportionality analysis revealed significant signals for drug ineffectiveness (n = 2,108, ROR = 1.6, PRR = 1.6, chi(2) = 483.4, IC = 0.7, EBGM = 1.6), drug hypersensitivity (n = 1,014; ROR = 4.9, PRR = 4.8, chi(2) = 2998.7, IC = 2.2, EBGM = 4.7), and anxiety (n = 198, ROR = 4.3, PRR = 4.2, chi(2) = 2202.0, IC = 2.0, EBGM = 4.1). Strongest signals (EBGM = 9.9) were observed for suicide attempt, agitated depression, and renal dysplasia. Tachycardia (EBGM = 8.3) was the most frequently reported adverse event among patients under 18 years, while emotional disorder (EBGM = 9.5) predominated in those aged 65 years and older. Most adverse events (39.3%) occurred within the first 30 days of venlafaxine therapy initiation. CONCLUSION: This pharmacovigilance analysis systematically identified significant safety signals associated with venlafaxine. The findings provide important evidence to support safer clinical use of venlafaxine and may assist in optimizing individualized therapeutic decisions in practice. |
|---|
| ジャーナル名 | Frontiers in pharmacology |
|---|
| Pubmed追加日 | 2026/2/6 |
|---|
| 投稿者 | Chokkakula, Santosh; Yang, Hualiang; Al-Masri, Abeer A; Zhang, Yiquan; Naveen, Bommireddy; Yang, Bing |
|---|
| 組織名 | Department of Microbiology, Chungbuk National University College of Medicine and;Medical Research Institute, Cheongju, Republic of Korea.;Department of Pharmacy, Tianjin Central Hospital of Gynecology Obstetrics,;Tianjin, China.;Department of Physiology, College of Medicine, King Saud University, Riyadh,;Saudi Arabia.;School of Pharmacy, Tianjin Medical University, Tianjin, China.;Department of Chemical and Biological Engineering, Gachon University,;Seongnam-Si, Gyeonggi-do, Republic of Korea.;Department of Cell Biology, College of Basic Medical Sciences, Tianjin Medical;University, Tianjin, China.;Department of Public Health, International School, Krirk University, Bangkok,;Thailand. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/41646188/ |
|---|
